Sulfate ion

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Sulfate ion
Accession Number
DB14546
Description
Not Available
Type
Small Molecule
Groups
Experimental, Investigational
Structure
Thumb
Weight
Average: 96.063
Monoisotopic: 95.951729178
Chemical Formula
O4S
Synonyms
  • Sulfate
  • Sulfate dianion
  • Sulfate(2-)
  • Sulfuric acid ion(2-)

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Sulfate ion.
AclidiniumThe therapeutic efficacy of Sulfate ion can be decreased when used in combination with Aclidinium.
AlfentanilThe therapeutic efficacy of Sulfate ion can be decreased when used in combination with Alfentanil.
AlloinThe risk or severity of adverse effects can be increased when Sulfate ion is combined with Alloin.
AlmasilateThe therapeutic efficacy of Sulfate ion can be decreased when used in combination with Almasilate.
Aluminium phosphateThe therapeutic efficacy of Sulfate ion can be decreased when used in combination with Aluminium phosphate.
Aluminum hydroxideThe therapeutic efficacy of Sulfate ion can be decreased when used in combination with Aluminum hydroxide.
AmantadineThe therapeutic efficacy of Sulfate ion can be decreased when used in combination with Amantadine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Sulfate ion.
AmiodaroneThe therapeutic efficacy of Sulfate ion can be decreased when used in combination with Amiodarone.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Loa Freedom SCapsule100 g/1001OralLOA BIO INC.2020-11-09Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
RurinaSulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)LiquidTopicalNano Bio Tech Co.,Ltd2017-07-01Not applicableUS flag
RurinaSulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)LiquidTopicalTELOM-X GENE Co., Ltd.2017-07-01Not applicableUS flag
Telom-X-geneSulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)LiquidTopicalTELOM-X GENE Co., Ltd.2017-07-01Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Loa Freedom SSulfate ion (100 g/1001)CapsuleOralLOA BIO INC.2020-11-09Not applicableUS flag
RurinaSulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)LiquidTopicalNano Bio Tech Co.,Ltd2017-07-01Not applicableUS flag
RurinaSulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)LiquidTopicalTELOM-X GENE Co., Ltd.2017-07-01Not applicableUS flag
Telom-X-geneSulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)LiquidTopicalTELOM-X GENE Co., Ltd.2017-07-01Not applicableUS flag

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
7IS9N8KPMG
CAS number
14808-79-8
InChI Key
QAOWNCQODCNURD-UHFFFAOYSA-L
InChI
InChI=1S/H2O4S/c1-5(2,3)4/h(H2,1,2,3,4)/p-2
IUPAC Name
sulfate
SMILES
[O-]S([O-])(=O)=O

References

General References
Not Available
Human Metabolome Database
HMDB0001448
ChemSpider
1085
BindingDB
26992
RxNav
1426598
ChEBI
16189
PDBe Ligand
SO4
Wikipedia
Sulfate
PDB Entries
101m / 102m / 103m / 104m / 105m / 106m / 107m / 108m / 109m / 110m
show 21162 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticCathartic Colon1
4CompletedTreatmentInflammatory Bowel Diseases (IBD) / Iron Deficiency1
4Not Yet RecruitingTreatmentAnemia of Prematurity / Very Low Birth Weight Infant1
4RecruitingTreatmentChronic Kidney Disease (CKD) / Kidney Insufficiency, Chronic1
4Unknown StatusDiagnosticColonoscopy1
4Unknown StatusDiagnosticPreeclampsia1
4Unknown StatusTreatmentDeep Neuromuscular Blockade / Magnesium Sulfate / Neuromuscular Blockade / Rocuronium1
4Unknown StatusTreatmentInflammatory Bowel Diseases (IBD) / Iron Deficiency Anemia (IDA)1
4Unknown StatusTreatmentIron Deficiency Anemia (IDA) / Iron-Deficiency Anemias / Pregnant State1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Undifferentiated Leukemia (AUL) / Childhood T Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral100 g/1001
LiquidTopical
SolutionIntravenous12 g/L
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.84ChemAxon
pKa (Strongest Acidic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.26 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity11.53 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on July 12, 2018 21:40 / Updated on June 12, 2020 16:53